The FDA is seeking public feedback ahead of a summer meeting to evaluate its voucher pilot program, which has accelerated four drug approvals since its creation last June. The agency plans to assess the program's progress and gather stakeholder input on its effectiveness.
The voucher pilot represents part of broader efforts to streamline drug approval processes while maintaining safety standards. Such programs typically aim to reduce regulatory timelines for certain categories of medications, though specific details about eligibility criteria were not provided in available sources.